A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib significantly reduces CCL5 expression and was well tolerated at week 24, meeting coprimary endpoints. Brepocitinib reduces inflammatory biomarker expression and improves clinical severity, while maintaining favorable safety profile.
Authors
- Ester Del Duca (ORCID: https://orcid.org/0000-0001-7948-8536)
- Ping Mahling (ORCID: https://orcid.org/0000-0003-0560-2214)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Swaroop Bose (ORCID: https://orcid.org/0000-0002-4337-9490)
- Kelly Hawkins (ORCID: https://orcid.org/0000-0002-9281-230X)
- Barry S. Oemar (ORCID: https://orcid.org/0000-0003-1996-5817)
- Eden David (ORCID: https://orcid.org/0000-0001-9666-4132)
- Yeriel Estrada (ORCID: https://orcid.org/0000-0002-5172-6747)
- Benjamin Ungar (ORCID: https://orcid.org/0000-0003-0882-8163)
- Elena Peeva
- Juliana Pulsinelli (ORCID: https://orcid.org/0000-0002-1014-3940)
- Celina Dubin
- Neda Shokrian
- Joel Corrêa da Rosa (ORCID: https://orcid.org/0000-0003-4221-1976)
- Marguerite Meariman (ORCID: https://orcid.org/0000-0001-5931-3106)
- Elizabeth Andrews (ORCID: https://orcid.org/0000-0003-1131-5983)
- Giselle Singer
- Savina Sikand
Institutions
- University of Rome Tor Vergata (IT)
- Albert Einstein College of Medicine (US)
- Pfizer (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1016/j.jaad.2024.09.073
- Citations
- 18
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 7.65
Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Celgene
- Regeneron Pharmaceuticals
- Dermira
- Incyte
- Castle Biosciences
- Glenmark Pharmaceuticals
- Galderma
- LEO Pharma